Metacrine plans to use proceeds from the Series C financing to advance its clinical development pipeline, including its lead candidate MET409 for the potential treatment of NASH, IBS-D, and inflammatory bowel disease, and to expand its pipeline through continued internal discovery efforts. A Phase 1 clinical study of MET409 is planned to begin later this month.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

3985 Sorrento Valley Blvd. C
San Diego, CA 92121
USA

Phone

(858) 369-7800

Website

www.metacrine.com

Email Address

[email protected]

Overview

Metacrine (Nasdaq: MTCR) is a biotech company founded in 2015 on technology licensed from the laboratory of Dr. Ronald Evans, a world leader in nuclear hormone receptors and Howard Hughes Medical Institute Investigator at the Salk Institute.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Preston Klassen

Chief Financial Officer

Trisha Millican

Vice President

Nicholas Smith

VP - Operations

Eric Bischoff

Browse more venture capital transactions:

Prev: 6/8/2018: Zebra Medical Vision venture capital transaction
Next: 6/8/2018: Devo venture capital transaction

Share this article

Where The Data Comes From

We do our best to document every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary